Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine the effect of hybrid closed loop on glycemic outcomes in young patients aged between 15 and 25 years old with type 1 diabetes, whatever is their initial metabolic control.
Type 1 diabetes (T1D) constitutes a major public health challenge due to acute complications requiring emergency hospitalizations, as well as many chronic complications that need to be managed over the long term. However, these complications can be prevented by maintaining correct glycemic control, according to international guidelines.
For the past few years, the arrival of new technologies as insulin pump and particularly Continuous Glucose Monitoring (CGM) showed a significant improvement on metabolic control.
Nevertheless, adolescents and young adults with type 1 diabetes need a special focus because they still fail to meet glycemic control targets.
At this time, hybrid closed loop, pairing Continuous Glucose Monitoring with insulin pump, enables insulin delivery in a semi-autonomous way thanks to algorithms, and leads to the best metabolic results we've never got in randomized trials and real-world studies.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group1 | Patients between 15 and 25 years old with type 1 diabetes and treated by hybrid closed loop |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Hybrid closed loop (HCL) | Device |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| HbA1c after HCL | Comparison of HbA1c (%) before and after HCL (at least 3 months of use) | at 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| HbA1c after HCL | Comparison of HbA1c (%) before and after HCL (at least 3 months of use) | at 6 months |
| HbA1c after HCL | Comparison of HbA1c (%) before and after HCL (at least 3 months of use) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Tertiary care center from Centre Hospitalier Sud Francilien
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Juliette EROUKHMANOFF, MD | Centre Hospitalier Sud Francilien | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre Hospitalier Sud Francilien | Corbeil-Essonnes | 91106 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40208827 | Derived | Ung M, Penfornis A, Valentim C, Franc S, Amadou C, Eroukhmanoff J. Hybrid Closed Loop in Adolescents and Young Adults Living with Type 1 Diabetes: A Real-World Study. Diabetes Technol Ther. 2025 Sep;27(9):760-764. doi: 10.1089/dia.2024.0528. Epub 2025 Apr 10. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003922 | Diabetes Mellitus, Type 1 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| at 12 months |
| HbA1c after HCL | Comparison of HbA1c (%) before and after HCL (at least 3 months of use) | at 24 months |
| Use of HCL | Percentage of use of HCL | at 3 months |
| HCL stop | number of HCL stop | at 3 months |
| Glycemic parameters with CGM | pourcentage time In Range (TIR) 70-180 mg/dl | at 3 months |
| Glycemic parameters with CGM | pourcentage time Below Range (TBR) < 70 mg/dl | at 3 months |
| Glycemic parameters with CGM | pourcentage Coefficient of Variation (CV) | at 3 months |
| keto-acidosis and severe hypoglycemia | Comparision of keto-acidose and severe hypoglycemia events the year before HCL and after HCL | at 3 months |
| retinopathy | Comparison of retinography results before HCL and after HCL | at 3 months |
| nephropathy | Comparison microalbuminuria/creatininuria dosage the year before HCL and after HCL | at 3 months |
| D004700 | Endocrine System Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |